美股异动丨赛诺菲盘前跌超4%,预计旗下重磅药物tolebrutinib的监管审查将延迟
Core Viewpoint - Sanofi (SNY.US) shares fell over 4% in pre-market trading, currently priced at $46.65, following news regarding the regulatory review timeline for tolebrutinib in the U.S. [1] Group 1 - Sanofi anticipates that the U.S. regulatory review process for tolebrutinib, intended for non-relapsing secondary progressive multiple sclerosis (nrSPMS), will exceed the previously communicated target action date of December 28, 2025 [1] - The company expects to receive further guidance from the FDA by the end of the first quarter of 2026 [1]